Mid Atlantic Retina
14
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
84.6%
-1.9% vs industry average
0%
0 trials in Phase 3/4
36%
4 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Role: collaborator
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
Role: collaborator
Quality and Diagnostic Utility of Mydriatic Fundus Plenoptic Photography
Role: collaborator
Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy
Role: lead
Handheld Vibrator Versus Topical Eye Drops as Anesthesia for Intravitreal Injections
Role: collaborator
Eplerenone for the Treatment of Central Serous Chorioretinopathy
Role: collaborator
Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane
Role: collaborator
Inflammasomes in Cell Death in FTMH, ERM, and RRD
Role: collaborator
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Role: collaborator
30g vs 33g Needle for Intravitreal Injections
Role: collaborator
Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation
Role: collaborator
Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments
Role: lead
A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
Role: lead
Omega-3-fatty Acids on Age-related Macular
Role: lead
All 14 trials loaded